Although not statistically significant, the bone marrow infection rate (40.0% vs. 18.2%; p=0.103), double hit/triple-hit lymphoma incidence (21.1% vs. 0%; p=0.163), TP53 mutation rates (50% vs. 26.3%; p= 0.129), and bendamustine usage before leukapheresis (7.7% vs. 0%; p=0.189) were higher in the T-defect group than in the T-normal group. Here, TP53 is linked to lymphoma.